Biogen Idec’s Tysabri Approved for Crohn’s

Biogen Idec (NASDAQ: BIIB) of Cambridge, MA, and Ireland’s Elan announced this afternoon that the FDA has granted an expanded approval for their drug Tysabri as a treatment for Crohn’s disease. The drug was previously approved to treat multiple sclerosis.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy